长春高新上半年研发投入同比增长17.32% 加速从单一产品向多元化布局

Core Viewpoint - Changchun High-tech's revenue and net profit have declined in the first half of 2025, attributed to strategic adjustments and increased innovation investments [2] Financial Performance - In the first half of 2025, the company achieved revenue of 6.603 billion yuan, a year-on-year decrease of 0.54% [2] - The net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - Research and development (R&D) investment reached 1.335 billion yuan, an increase of 17.32% compared to the same period last year, with R&D expenses accounting for 20.21% of revenue [2] Strategic Initiatives - The company is transitioning from a single product focus to a diversified layout, emphasizing technology innovation as a core driver of development [2] - Changchun High-tech is leveraging artificial intelligence (AI) to enhance drug research and has established seven enterprise-level intelligent platforms to promote digital transformation [2][3] Product Development - In the growth hormone sector, Changchun High-tech maintains a leading market share in China, with its subsidiary, Changchun Jinsai Pharmaceutical, generating revenue of 5.469 billion yuan, a 6.17% increase year-on-year [3] - The company has launched its first innovative drug for gout treatment, Jinbeixin® (伏欣奇拜单抗), which is the first fully human monoclonal antibody targeting IL-1β in China [5] - Changchun High-tech is expanding its innovative gene engineering pharmaceutical business, focusing on children's and women's health, as well as key areas like endocrine metabolism and oncology [4] Future Outlook - The company plans to continue its focus on the pharmaceutical industry, increasing R&D investments and introducing cutting-edge products and technologies, while targeting high-burden diseases prevalent in both China and the U.S. [5]